Drugs / GSK1004723
last change Aug 2009 re-read 2 minutes ago

GSK1004723

Small molecule targets HRH1, HRH3 via inhibition

Developed for
seasonal allergic rhinitis · allergic rhinitis
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00694993 Dec 2007 → May 2008 seasonal allergic rhinitis GlaxoSmithKline Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00972504 Comparator Jun → Aug 2009 seasonal allergic rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00824356 Comparator Jun → Aug 2008 allergic rhinitis GlaxoSmithKline Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as GSK1004723 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00694993
2

NCT00972504

NCT00824356

Action Inhibit “Histamine H3 receptor antagonist” CHEMBL1767164
2

“Histamine H1 receptor antagonist” CHEMBL1767164

“H1/H3 dual antagonist compound” NCT00694993

Modality Small molecule CHEMBL1767164
Route Intranasal intranasal spray administration” NCT00694993
Target HRH1 “Histamine H1 receptor antagonist” CHEMBL1767164
Target HRH3 “Histamine H3 receptor antagonist” CHEMBL1767164